For pharmaceutical companies, 2015 is landmark significance of the year, but how the trend of the development of the pharmaceutical companies in 2016? Said the industry, the new year, pharmaceutical companies to seek a breakthrough, must be to understand the future trend of medical service market monitor manufacturers.

Pharmaceutical companies facing the challenges of a long cycle, the crisis does not appear immediately, but if not early layout, is likely to eventually face dilemma of complete loss of competitive advantage. Health care reform to promote the market reform is very critical variables, must learn in the changeable market to grasp the trends and timely adjustment of strategies.

To pharmaceutical companies, the 2015 is landmark significance of the year: Although the development and Reform Commission to cancel the drug price caps, but the local government leading drug bidding has become more and more severe, the greater challenge is the channel with the largest pharmaceutical companies, hospitals are faced with the unprecedented reform. In a series of reforms, the interests of hospitals and doctors on drugs are the most important considerations. Both directly suppress prices or to the hospital reform and policy side thrust is to control the increasing medical expenses, while accounting for the main part of medical expenses drug naturally become the biggest cost control object.

And whether near the end of the year, sure to control drug prices for core of Sanming mode access to policy, the further direction for public hospital reform are given in the 2016. Single on 2015, the introduction of intensive public hospital reform policy, pharmaceutical companies are huge challenges in 2016. First, the hospital drug addition in a number of provinces have been in full swing, the drug became the cost center of the hospital rather than the profit center, which is the compression of the hospital drug procurement impulse. At the same time, the policy also mandated that the proportion of hospital revenue in 2017 must be decreased to less than 30%. , of course, based on past experience, these policies are the way to avoid, such as pharmacy trusteeship and the bigger hospital revenue denominator. However, with the threat of medical insurance in the end closer and closer, the demand for policy to promote the fine management will also become increasingly urgent, to avoid the arrival of the crisis can only delay the arrival of the challenge can not be resolved.

The large-scale development of pharmaceutical companies has now entered the bottleneck period, innovation ability and health decline control the tightening of the fee is to restrict the main factor for the pharmaceutical development. The enhancement of innovation is open, but in response to the cost control, insurance market share, is more urgent for pharmaceutical companies. Chinese local pharmaceutical companies, their innovation ability is weak, the government's response to the control of the hospital channel is more important.

Pharmaceutical companies to seek a breakthrough, must be to understand the medical service market and the trend of the future: first of all, to control the medical behavior will seriously affect the development of channels of the hospital. Under the pressure of the cost control, the government has to understand it is unable to solve the problem of rapid increase of drug costs alone to suppress prices, is gradually from the hospital and doctor of management control. Therefore, although the policy is more extensive, but the future development through the development of clinical pathway can effectively control the behavior of the doctor, such as PBM, will help control health care medical behavior. This will ultimately promote the fine control of the medical behavior, so that the present effective methods of avoiding failure.

Secondly, the price and the effect will be simultaneously. Although policy is currently mainly fixed prices, trying to control prices for medicines to control medical costs in the short term through, but with promotion of clinical path of promotion and grading treatment effect will become an important assessment indicators. The higher cost of drugs can get a broader market. Those who blindly through low prices but less effective drugs will be affected. Therefore, some rely on low prices competition but the lack of efficacy of the product will eventually be phased out. This is mainly due to fine management can effectively track treatment results in order to determine the optimal price of the drug.

Again, the cooperation will promote the transformation of active pharmaceutical procurement. Class GPO and IDNs mode will in China to test the water gradually, joint procurement of medical cooperation organization will have help pharmaceutical companies the amount of change in price, driven by pharmaceutical companies to further. Even if the future out of hospital outpatient pharmacy, hospital pharmacy procurement volume is still huge, facing the medical behavior increasingly stringent controls, hospital cost cutting power will gradually strengthen. This led to the hospital joint procurement needs to reduce the price by a large volume of procurement negotiations. This joint procurement will become more market-oriented, rather than mandatory government designated, joint procurement will also be considered from the two aspects of price and effect, rather than a simple brush.

Finally, the decomposition of hospital channel forcing pharmaceutical companies focus more retail. With the reform deepening, outpatient pharmacy moved out of the hospital and other fundamental measures may be introduced, which depend on in hospital channel of pharmaceutical companies will have a great impact. Therefore, ahead of the layout of the retail terminal is visionary companies need to consider. The future will be successful to do service in the retail channel, which helps companies improve service ability complete transformation. Pharmaceutical companies to provide retail channels is not only products, and more is with retail channels jointly developed a set of solutions, to overall patient pharmaceutical services to.

Therefore, pharmaceutical companies to cope with the challenges we must conform to the trend of the market in the future, from the current product sales for the value orientation of the channel to a service oriented pay more attention to the effect of direct user oriented value of mining.

In such a market orientation, pharmaceutical companies need to make changes in many aspects, first, improve the hospital supply channels. Although the pharmaceutical companies can go through hosting pharmacy